Adel Zakharia, Resident Physiciana at NYC Health + Hospitals, shared a post on X:
“New paper out in Clinical Lung Cancer.
Does consolidation durvalumab improve in-field local control after chemoRT for stage III NSCLC? 233 patients. 696 lesions.
- Durvalumab improves PFS and OS, but not in-field local recurrence
- Local failures occurred predominantly at bulky disease sites (MTV >25cc)
- Durvalumab’s survival benefit appears driven by out-of-field disease control
We still need better strategies to control bulky tumors locally, even in the durvalumab era.
Grateful to Nitin Ohri, Balazs Halmos and all co-authors.
Title: Impact of Consolidation Durvalumab on Local Control Following Chemoradiotherapy for Non–Small Cell Lung Cancer
Authores: Adel Zakharia, William Bodner, Balazs Halmos, Madhur Garg, Rasim Gucalp, Haiying Cheng, Brendon Stiles, Nitin Ohri.
Other articles about Lung Cancer on OncoDaily.